iRhythm Technologies stock
IRTCNASDAQiRhythm Technologies, Inc., HealthcareISIN US4500561067
30Score 30 out of 100, Weak
Price and trend
28 / 100
Price history
−48% in one yearThe chart shows daily closes over 10 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 22% below it.
Since February 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 32).
The price is 51% below its 52-week high. Largest decline in 10 years: 84% (January 2021 to August 2021).
Chart figures for advanced users
- SMA 50$112.39
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$119.88
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)32
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$86.06
- The lowest closing price of the last twelve months.
- Resistance$189.25
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- iRhythm Technologies, Inc. belongs to the Medical (Devices) industry (United States) and, with a market value of $3.1B, is number 34 of 90 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $747.14M (up 26.2% year on year) and a loss of $44.55M.
- For fiscal 2026, analysts expect on average revenue of $892.44M (up 19.4%) and adjusted earnings per share of −$0.83.
Show more
- MEQIRI Score 30 out of 100 (Weak): rank 690 of 714 in Healthcare, median 53.
- Our model puts fair value at $50.75, with the price 75% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 23% a year since 2020, Medical (Devices) median 13.8%.Growth 70
Weaknesses
- High debtDebt 4.1 times equity (latest quarter), Medical (Devices) median 0.47.Stability 32
- Above fair valuePrice 75% above the fair value of $50.75.Valuation 23
- Loss-makingLoss of $38.59M over the last 12 months.Fundamentals 17
Its standout strength is growth, while fundamentals and momentum hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
- price far below its 52-week high
- weak momentum
What lowers it
- price not overheated over the past year
Valuation
Valuation signal
Significantly overvaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $36.25 and expensive above $84.58 (uncertainty high, based on the price swings of the past year).
Calculated with a cost of equity of 9.1%. At 10.1% the fair value would be $42.63, at 8.1% it would be $62.67.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 21.6% on the twelve months before. Revenue has grown strongly since 2013, at around 38% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 71%, operating −5%, net −6%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 18 Feb 2027in 98 days
- Last reported
- 5 Nov 2026EPS reported $0.82 (expected $0.02)above expectations
Analyst estimates
Analysts have cut their 2026 earnings estimate by 304.0% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −$0.83−304.0%
- Revenue
- $892.44M+0.2%
- Earnings per share
- $1.26+8.2%
- Revenue
- $1.07B+1.1%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +2.7%2026 guidance raised: revenue of $880 million to $890 million (up 18% to 19%) and adjusted EBITDA margin of 13% to 14%.
“We are raising full year 2026 revenue guidance to $880 million-$890 million, representing 18%-19% year-over-year growth.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 9 insiders sold, $7.72M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Wilson Daniel G.Sale
2 Sept 2026, Chief Financial Officer
- Shares
- 773
- Price
- $121.83
- Value
- $94,175
- Blackford Quentin S.Sale
10 Aug 2026, President and CEO
- Shares
- 26,859
- Price
- $124.65
- Value
- $3.35M
- Murphy Patrick MichaelSale
10 Aug 2026, CBO and CLO
- Shares
- 7,093
- Price
- $124.65
- Value
- $884,156
Show 8 more
- Patterson ChadSale
10 Aug 2026, CHIEF COMM & PRODUCT OFFICER
- Shares
- 7,093
- Price
- $124.65
- Value
- $884,170
- Shrishrimal SumiSale
10 Aug 2026, EVP, Chief Risk Officer
- Shares
- 5,372
- Price
- $124.65
- Value
- $669,641
- Turakhia MinangSale
10 Aug 2026, CHIEF MED/SCI OFCR EVP ADVTECH
- Shares
- 7,093
- Price
- $124.65
- Value
- $884,151
- Smith MervinSale
3 Aug 2026, EVP Strategic Business Ops
- Shares
- 617
- Price
- $122.12
- Value
- $75,349
- Rodda JulianneSale
3 Aug 2026, EVP, CHIEF PEOPLE OFFICER
- Shares
- 2,112
- Price
- $122.12
- Value
- $257,919
- Patterson ChadSale
3 Aug 2026, CHIEF COMM & PRODUCT OFFICER
- Shares
- 2,712
- Price
- $122.12
- Value
- $331,192
- Turakhia MinangSale
2 Jul 2026, CHIEF MED/SCI OFCR EVP ADVTECH
- Shares
- 1,423
- Price
- $124.71
- Value
- $177,462
- Freeman Sean ClintonSale
2 Jul 2026, EVP, Strategy & Corp Devt
- Shares
- 918
- Price
- $124.71
- Value
- $114,484
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at iRhythm Technologies
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 30
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- Integer HoldingsITGR $4.31B58
- AxoGenAXGN $3.5B46
- AmbuAMBU-B.CO $3.41B70
- TransMedics GroupTMDX $3.2B57
- GN Store NordGN.CO $2.67B55
- NeogenNEOG $2.53B42
- UFP TechnologiesUFPT $2.43B77
- ElektaEKTA-B.ST $2.29B56
ETFs that hold iRhythm Technologies
Held by 16 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Global X Telemedicine & Digital Health UCITS ETFDDOC | 3.43% | 0.68% | €5.31M |
| Harbor Health Care UCITS ETF AccW311 | 1.38% | 0.89% | €11.61M |
| L&G Healthcare Technology & Innovation UCITS ETFXMLH | 1.10% | 0.49% | €318.39M |
Show 5 more
| iShares Ageing Population UCITS ETF2B77 | 0.26% | 0.40% | €807M |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.13% | 0.30% | €185.82M |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.10% | 0.30% | €2.17B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.09% | 0.30% | €4.22B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.06% | 0.43% | €2.48B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Jun 2022)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.